Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

O. Caffo, E. Biasco, G. Facchini, L. Fratino, D. Gasparro, C. Mosillo, U. Basso, D. Santini, M. Tucci, C. Ortega, F. Verderame, S. Scagliarini, G. L.O. Re, G. Procopio, G. Fornarini, E. Campadelli, R. Sabbatini, F. Maines, U. De Giorgi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)vi252
JournalAnnals of Oncology
Publication statusPublished - Oct 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this